Author pages are created from data sourced from our academic publisher partnerships and public sources.
Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes.
- S. Baroletti, C. Piovella, J. Fanikos, M. Labreche, J. Lin, S. Goldhaber
- Thrombosis and haemostasis
- 14 November 2008
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction that occurs following exposure to unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). HIT with… Expand
Multi-screen electronic alerts to augment venous thromboembolism prophylaxis.
Venous thromboembolism (VTE) prophylaxis in high-risk patients is frequently underutilised. We previously devised a one-screen computer alert program that identified hospitalised patients at high… Expand
Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry
- P. Prandoni, J. Trujillo-Santos, +5 authors M. Monreal
- Journal of thrombosis and haemostasis : JTH
- 1 November 2010
Although there is emerging evidence that bleeding is a strong predictor of mortality in patients with acute arterial thrombosis receiving antithrombotic therapy [1–3], whether a similar association… Expand
Fondaparinux in the initial and long-term treatment of venous thromboembolism.
BACKGROUND Even in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday… Expand
Incidence of arterial embolism in patients on treatment with old and new anticoagulants for venous thromboembolism.
- P. Prandoni, M. Milan, +4 authors F. Bilora
- Seminars in thrombosis and hemostasis
- 17 February 2015
The separate nature of venous and arterial thrombotic disorders has recently been challenged. Patients with venous thromboembolism (VTE) have an increased risk of subsequent symptomatic arterial… Expand
Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
Once anticoagulation is stopped, the risk of recurrent venous thromboembolism (VTE) over years after a first episode is consistently around 30%. This risk is higher in patients with unprovoked than… Expand
The value of 64-detector row computed tomography for the exclusion of pulmonary embolism.
Recently, a diagnostic strategy using a clinical decision rule, D-dimer testing and spiral computed tomography (CT) was found to be effective in the evaluation of patients with clinically suspected… Expand
Venous thromboembolism and arterial complications.
- P. Prandoni, C. Piovella, R. Pesavento
- Seminars in respiratory and critical care…
- 1 April 2012
An increasing body of evidence suggests the likelihood of a link between venous and arterial thrombosis. The two vascular complications share several risk factors, such as age, obesity, smoking,… Expand
Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry
- C. Piovella, F. Dalla Valle, +8 authors And the Riete Investigators
- Internal and Emergency Medicine
- 17 May 2014
Stratification of the individual bleeding risk prior to initiation of anticoagulation in patients with acute venous thromboembolism (VTE) has the potential to assist clinicians in making decisions… Expand
What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?
- P. Prandoni, C. Piovella, L. Filippi, V. Vedovetto, F. Dalla Valle, A. Piccioli
- Expert opinion on pharmacotherapy
- 19 March 2014
Introduction: Venous thromboembolism (VTE) is a frequent complication in patients with malignancies. The treatment of VTE disorders in cancer patients remains a difficult clinical task. Areas… Expand